Emily S. Finn is assistant professor of psychological and brain sciences at Dartmouth College, where she directs the Functional Imaging and Naturalistic Neuroscience (FINN) Lab. Finn has pioneered techniques such as functional connectome fingerprinting and connectome-based predictive modeling for predicting individual behaviors from functional brain connectivity. Her current work is focused on how within- and between-individual variability in brain activity relates to appraisal of ambiguous information under naturalistic conditions such as watching movies or listening to stories.
Emily S. Finn
Assistant professor of psychological and brain sciences
Dartmouth College
From this contributor
To improve big data, we need small-scale human imaging studies
By insisting that every brain-behavior association study include hundreds or even thousands of participants, we risk stifling innovation. Smaller studies are essential to test new scanning paradigms.
To improve big data, we need small-scale human imaging studies
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.